I rise today to talk about the vote we just had on the motion to proceed on the GENIUS Act. Despite promises that the GENIUS Act's fundamental flaws would be fixed ahead of any vote, we still don't have the new bill text. Now, many of my colleagues have made clear that they want to improve this bill and that it is important for Republicans not to jam us. Well, the Republicans decided to jam us anyway. But the Democrats have power to say no, and that is exactly what we just did. The GENIUS Act would establish a new regulatory framework for stablecoins, a type of cryptocurrency whose value is pegged to the value of another asset, often, the U.S. dollar. This is a $100 billion market. A stablecoin is very similar to a bank deposit. Its value, like the value of your deposits in a bank account, is supposed to maintain a stable value. That is why they call it a stablecoin. But as we have learned throughout history, banking can be a really risky activity. It requires a robust regulatory and supervisory framework that protects consumers, that protects our national security, and that protects the stability of the financial system. Democrats in the Banking Committee worked hard to improve the GENIUS Act before, during, and after we had a vote in committee on the bill. We want to strengthen the guardrails on this new financial product to make sure that it is safe and reliable.…
Share
More from Elizabeth Warren
Trump refused to sign it, but he couldn’t stop it. This law is groundbreaking. It will build more housing, bring down costs, and for the first time, stop private equity from buying up homes.
“Trump’s FCC Chair is trying to illegally rewrite the rules to make it easier for billionaires to line their own pockets while jacking up costs and controlling what Americans watch. After rubber-stamping the Nexstar-Tegna megamerger, this…
The Trump administration’s military adventurism overseas, combined with its obvious disregard for civilians, do not make the American people or our service members safer.
We need more visibility into what’s happening in these transactions when it has the potential to influence such an important part of our pharmaceutical chain.





